Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00769314 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Clinical Study for the Treatment of Cold Sore
A Phase 3 study of Herpes Labialis, sponsored by Valerio Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,727
- Enrollment target
- 20
- Study locations
NCT00769314 is a Phase 3 study of Herpes Labialis that has completed, run by Valerio Therapeutics. The registered enrollment target is 1,727 participants, above the 775-participant average among 6 other Herpes Labialis trials with a reported enrollment target (123% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT00769314, a Phase 3 study of Herpes Labialis, has completed, sponsored by Valerio Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,727 participants
- Enrollment target
- 20
- Study locations
Study Summary
To demonstrate the efficacy of a single dose of acyclovir Lauriad® 50mg muco-adhesive buccal tablet versus a single dose of matching placebo on the primary vesicular lesion of cold sore.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Acyclovir Lauriad
Study Locations (20)
Other
- Taylor Square Private Clinic - Sydney
- Central Brunswick Medical Centre - Sydney
- General Teaching Hospital, Dep. Of Dermatology - Opava
- U zastavky 16 - Opava
- Central military hospital Dept. of Dermatology - Prague
- University Hospital Bulovka 3rd Clinic of Inf. Diseases - Prague
- University Hospital Bulovka Dept. of Dermatology - Prague
- Hôpital St Jacques Service de Dermatologie - Besançon
- Private Practice - Martigues
- Hopital Fournier, Service de dermatologie - Nancy
Arizona
- Radiant Research, Inc., - Scottsdale
- Radiant Research, Inc., - Tucson
New York
- Rochester Clinical Research, Inc., - Rochester
- Stony Brook University Medical Center - Stony Brook
Texas
- Center for Clinical Studies - Houston
- Center for Clinical Studies, Ltd., LLP. - Houston
California
- Dermatology Private Practice - San Francisco
Colorado
- Front Range Clinical Research - Wheat Ridge
Idaho
- St. Luke's Family Health, - Meridian
Missouri
- Clinvest, a Division of Banyan Group, Inc., - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,727 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00769314
The ClinicalTrials.gov registry entry for NCT00769314 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,727 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 775-participant average among 6 other Herpes Labialis trials with a reported enrollment target (123% higher). The listed sponsor is Valerio Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Herpes Labialis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00769314 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Arizona, New York.
Frequently Asked Questions
What is clinical trial NCT00769314 about?
NCT00769314 is a clinical study titled "Phase 3 Clinical Study for the Treatment of Cold Sore". To demonstrate the efficacy of a single dose of acyclovir Lauriad® 50mg muco-adhesive buccal tablet versus a single dose of matching placebo on the primary vesicular lesion of cold sore.
What is the current status of trial NCT00769314?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,727 participants. The study started on 2007-05. Estimated completion is 2009-08.
What conditions does trial NCT00769314 study?
This clinical trial studies the following conditions: Herpes Labialis.
What interventions are being tested in trial NCT00769314?
The interventions under investigation include: Placebo (DRUG), Acyclovir Lauriad (DRUG).
Who is sponsoring clinical trial NCT00769314?
This trial is sponsored by Valerio Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00769314 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Idaho, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Herpes Labialis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old
COMPLETED · Phase 3
-
Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis
COMPLETED · Phase 3
-
Viral Infections in Healthy and Immunocompromised Hosts
RECRUITING
-
Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis
COMPLETED · Phase 2
-
Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis
COMPLETED · Phase 2
-
Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.